Bayer's Bold Bet: A Late-Stage Eye Disease Drug to Revive Its Pipeline

Bayer has acquired PER-001, a drug in late-stage development for eye diseases. The move marks a shift in strategy after years of focusing on early-stage innovations. The deal also signals a return to larger-scale acquisitions following the costly Monsanto takeover and its legal fallout. PER-001 is an endothelin receptor antagonist currently in Phase II trials. It targets glaucoma and diabetic retinopathy, conditions with significant unmet medical needs. Bayer believes the drug could become a disease-modifying therapy, offering long-term benefits beyond existing treatments.

The acquisition strengthens Bayer’s ophthalmology portfolio, which has relied heavily on Eylea. That franchise now faces growing pressure as key patents near expiry. By securing PER-001, the company aims to reinforce its pipeline and protect mid-term revenue.

This deal is Bayer’s first late-stage acquisition since the Monsanto purchase in 2018. That takeover led to years of litigation and financial strain. In contrast, recent years saw the company invest nearly USD7 billion in early-stage firms like ASK Bio, Vividion, and Kandy Therapeutics. The PER-001 acquisition expands Bayer’s ophthalmology offerings while addressing patent challenges. It also reflects a broader strategy shift toward advanced clinical programmes. The company now aims to balance innovation with revenue stability in the coming years.